Medicine for dentin hypersensitivity
Our synthetic peptide (KH001) regenerates damaged dentine restoring its original thickness and sunsequently reducing hypersensitivity.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Others
- Production method
- OEM
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- dental products
- Category
- Medicines
HysensBio
- Verified Certificate
-
1
Product name | Medicine for dentin hypersensitivity | Certification | - |
---|---|---|---|
Category | Medicines | Ingredients | - |
Keyword | dental products | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | South Korea | Stock | 100 |
Supply type | OEM | HS code | - |
Product Information
KH001 - Dentin hypersensitivity
1. When dentinal tubules are exposed, odontoblasts in the dentinal tubules come into contact with external stimuli, such as hot or cold temperature and pressure. This contact triggers pulp nerves and leads to sharp pain known as dentin hypersensitivity.
2. Activated odontoblasts secrete dentin matrix to the intratubular dentinal tubules and occlude them. As a result, the dentin is restored back to its original state. This is the world’s first hypersensitivity treatment using HysensBio’s physiologic dentin regeneration.
3. Pre-existing treatments were to externally block the dentinal tubules using nonphysiologic dentin materials. In this case, outward hydrostatic pressure in the dentinal tubules causes the restorative materials to fall out.
4. However, treatment with Selcopintide regenerates the native dentin layer, filling in the exposed area and withstanding the pressure. Using this technology, we believe it is possible to fundamentally treat dentin hypersensitivity.
- Product Info Attached File
B2B Trade
Price (FOB) | Negotiable | transportation | Negotiation Other |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Others | Shipping time | Negotiable |
- President
- PARK JU CHEOL
- Product Category
- Medicines
- Year Established
- 2016
- Main Markets
-
Canada
Germany
Switzerland
U. Kingdom
U.S.A
- Main Product
Related Products
NOVA PMC
Multivita injection
BioDesign_Protein drug design platform
Novel small molecules for treating NASH
Lactomin